

PHARMACY AND THERAPEUTICS (P&T) COMMITTEE
August 12, 2020

The meeting of the Pharmacy and Therapeutics (P&T) Committee of the North Carolina State Health Plan for Teachers and State Employees (The Plan) was called to order at 6:30 P.M. (EST) on Wednesday, August 12, 2020, via webinar, accessible to the public through the Plan's website. Quorum was present.

MEMBERS PRESENT:

Sundhar Ramalingam, MD, Oncologist, Duke Cancer Center
Peter Robie, MD, General Internist, Wake Forest Baptist Community Physicians
Tony Gurley, RPh, JD, Owner/Pharmacy Manager, Glenwood South Pharmacy + Market
John J. Engemann, MD, Infectious Disease Specialist, Raleigh Infectious Disease Associates, PA
Joseph Shanahan, MD, Owner, Shanahan Rheumatology & Immunotherapy
David Konanc, MD, Neurologist, Raleigh Neurology Associates
John Anderson, MD, MPH, Chief Medical Officer, Duke Primary Care
Jennifer Burch, PharmD, Owner, Central Compounding Center
Matthew K. Flynn, MD, Founder, Family Dermatology

MEMBERS ABSENT:

None

PLAN & VENDOR STAFF:

Kautook Vyas, PharmD, Senior Pharmacy Consultant, Chairperson
Caroline Smart, Sr. Director, Plan Integration, State Health Plan
Dee Jones, Executive Director, State Health Plan
Natasha Davis, Sr. Pharmacy Benefits Program Manager, State Health Plan
Renee Jarnigan, RPh, Clinical Advisor, CVS Health
Stephanie R. Morrison, PharmD, BCPS, Clinical Advisor, CVS Health

Welcome:

The Chairperson welcomed the Committee members and guests to the webinar and performed roll call.

Conflict of Interest

In compliance with the requirements of Chapter 138A-15(e) of the State Government Ethics Act the Chairperson read the NCSHP's Ethics Awareness & Conflict of Interest Reminder to the P&T Committee members and requested that members who have either an actual or perceived conflict of interest identify the conflict and refrain from discussion and voting in those matters as appropriate. No conflicts of interest were noted.

Formulary Updates:

The Chairperson introduced CVS Caremark's Clinical Advisors Heather Renee Jarnigan, RPh, & Stephanie Morrison, PharmD, BCPS whom would be presenting CVS Caremark's Quarterly Formulary Updates, effective October 1, 2020. This included drug removals and additions to the formulary as well as tier changes and utilization management policies.

Ms. Jarnigan began by explaining that the Plan has a formulary exclusion exception process that is available to support Plan members who, per their provider, have a medical necessity to remain on an excluded drug. Ms. Jarnigan then reviewed the following products that will be excluded from the formulary starting on the effective date: Letairis Tab , Zydelig Tab, Aliqopa Via 60Mg, Inderal La Cap; Inderal XI Cap; Innopran XI Cap, Oxiconazole Cream And Oxiconazole Nitrate Cream 1%, Sucralfate Suspension 1Gm/10MI, Quazepam Tab , Fluoxetin(S) And Fluoxetine Tab 10Mg And 20 Mg, Bupap Tab And Butalb/Aceta 50-300Mg, Niacor And Niacin Tab 500Mg, Fenoprofen Tab 600Mg, Mytesi Tab 125Mg, Diphen Elx 12.5/5MI

All products being removed have therapeutic alternatives or generic equivalents that are covered as preferred products on the Plan's custom formulary.

Ms. Jarnigan identified all the branded products that will be moving to a non-preferred status, or up tiered. They included: Silenor Tab, Travatan Z, Moxeza Sol 0.5% Op, Cytomel Tab, Synalar Sol 0.01%.

Ms. Jarnigan along with Dr. Morrison identified all the medications that were being removed from CVS's New-to-Market block and would be available as covered products effective July 1, 2020, along with utilization management policies that went along with the new products and new molecular entities. The new medications being added to the formulary are as follows: Tukysa, Trodelvy, Tepezza, Vyndamax, Fintepla Sol 2.2Mg/MI, Xcopri Tab 50Mg.

There was no other opposition from the Committee members, so the other product additions were approved as presented.

The Committee was also presented with utilization management and line extensions. The line extensions were approved without opposition. Clinical utilization management rules for 2 therapies were discussed. The first was for Proton Pump Inhibitors. The Committee approved the utilization management for this therapy class. The second utilization management suggestion was for the medication Saxenda. The committee denied this suggestion due to concerns with the current pandemic and access to care.

Adjourn

Dr. Vyas addressed the Committee by thanking them for their service and informed them that the next meeting would be held on August 12, 2020 at 6:30 P.M. via webinar. The meeting was adjourned at approximately 8:03 P.M. (EST).



Kautook Vyas, Chair